Kailera Therapeutics, Inc.
No SEC Form 4 filings for $KLRA in the last 30 days.
See all $KLRA insider activity →Kailera Therapeutics (NASDAQ:KLRA) presented Phase 1 data for ribupatide at the EASD meeting, showing similar drug exposure and tolerability across injection sites. Partner Hengrui Pharma shared Phase 1 findings for HRS-4729, with 12 mg doses showing 16.0% weight loss and 67.3% liver fat reduction at Week 12. Kailera plans a Phase 1 trial for KAI-4729 outside China in 2026.
Kailera Therapeutics reported Phase 1 data showing its drug KAI-4729 achieved up to 16% mean weight loss at 12 mg over 12 weeks, with safety consistent with GLP-1s. The company's ribupatide showed similar exposure across injection sites.
Kailera Therapeutics (KLRA) presented Phase 1 data for ribupatide injection at EASD 2026, showing flexibility in injection sites. Partner Hengrui Pharma shared data on KAI-4729, showing 16.0% weight loss. Kailera plans Phase 1 trial for KAI-4729 outside China in 2026.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning KLRA (Kailera Therapeutics, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent KLRA coverage spans technology, financial news and regulation.
Positive Phase 1 results suggest potential efficacy and may drive near‑term buying interest.
Early‑stage weight‑loss data could boost investor optimism ahead of Phase 3, but the trial is still early and risk remains.
Positive Phase 1 safety and bioavailability data may boost investor confidence ahead of Phase 3.
Milestone moves the drug closer to mid‑2028 topline data, reducing development risk.
China regulatory progress for the same molecule can improve market expectations for Kailera’s licensed asset, though timing and geography differ.
AlphAI scores every news story that mentions KLRA with an AI model for sentiment and relevance, and aggregates insider trades from Kailera Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kailera Therapeutics (NASDAQ:KLRA) presented Phase 1 data for ribupatide at the EASD meeting, showing similar drug exposure and tolerability across injection sites. Partner Hengrui Pharma shared Phase 1 findings for HRS-4729, with 12 mg doses showing 16.0% weight loss and 67.3% liver fat reduction at Week 12. Kailera plans a Phase 1 trial for KAI-4729 outside China in 2026.
1 min readKailera Therapeutics reported Phase 1 data showing its drug KAI-4729 achieved up to 16% mean weight loss at 12 mg over 12 weeks, with safety consistent with GLP-1s. The company's ribupatide showed similar exposure across injection sites.
1 min readKailera Therapeutics (KLRA) presented Phase 1 data for ribupatide injection at EASD 2026, showing flexibility in injection sites. Partner Hengrui Pharma shared data on KAI-4729, showing 16.0% weight loss. Kailera plans Phase 1 trial for KAI-4729 outside China in 2026.
2 min readKailera Therapeutics (KLRA) completed enrollment in its global Phase 3 clinical program, KaiNETIC, for ribupatide injection, a GLP-1/GIP receptor dual agonist. The trials aim to treat obesity and overweight, with topline data expected in mid-2028. The program includes three trials with over 4,900 participants across 200 sites in 11 countries.
2 min readJiangsu Hengrui Pharmaceutical (HKEX: 01276) submitted HRS-7535, an oral GLP-1R agonist, for China approval in obesity and diabetes. The application follows positive Phase III trial results, with 180 mg dose achieving 11.1% weight loss. The drug is also being tested globally by Kailera Therapeutics (Nasdaq: KLRA).
7 min readKailera Therapeutics, Inc. (KLRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates • IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 • Ribupatide injection Phase 2b high-dose trial in obesi
6 min readThe article highlights Novo Nordisk (NVO) and Kailera Therapeutics (KLRA) as GLP-1-related stocks. Novo Nordisk launched oral Wegovy in January; it has surpassed 3 million U.S. prescriptions and received EU approval, contributing to better-than-expected Q1 results. Kailera, down 23% since its April IPO, reported phase 3 results in China for oral KAI-7535, with up to 11.1% mean weight loss after 50 weeks.
7 min readKailera Therapeutics (NASDAQ:KLRA) reported positive topline Phase 3 results for HRS-7535/KAI-7535, an oral GLP-1 receptor agonist, in obesity and type 2 diabetes trials. Obesity participants saw mean weight loss up to 10.9% by Week 44 and 11.1% by Week 50; HbA1c fell 1.50% to 1.68%. Safety showed no new signals. KLRA is also running a global Phase 2 trial starting April 2026, with results expected in 2027.
3 min read
